1. XVIIth ICW Conference, October 11–16, 1998, Rhodes, Greece. Targeting of influenza epitopes to murine CR1,2 using scFv antibodies. N225, Рrechl J., Horvath A., Kurucz I., Baiu D.С., Tchorbanov A., Hazenbos W., Rajnavolgyi E., Erdei A., Capel P. J. A.
2. 3rd Balkan Congress of Immunology, October 30th – November 1st, 2001, Athens, Greece. Antigen targeting by fusion single-chain hybrid antibodies. №105, Tchorbanov A., Рrechl J., Baiu D.С., Horvath A., Hazenbos W., Rajnavolgyi E., Erdei A., Capel P. J. A.
2003
3. II-nd National Congress of Immunology with International Participation, 30th May – June 1st, 2003, Sofia Bulgaria.
3.1. P3.6 Immunochemical analyses of Diphtheria toxoid produced using meat extract-based and semi-synthetic casein-based broths. Dimitrov J., Tchorbanov A., Vassilev T.
3.2. P4.9 Natural IgG Antibodies in intravenous Immunoglobulin (IVIg) preparations. Djoumerska I., Tchorbanov A., Pashov A., and Vassilev T.
3.3. P4.12 Reactivity of human natural IgG Autoantibodies to serum proteins is directed mainly to circulating Immunoglobulins. Djoumerska I., Voynova E., Tchorbanov A., Donkova-Petriny V., and Vassilev T.
3.4. P4.16 Breaking of tolerance to DNA in non-autoimmune mice by immunization with natural DNA/protein complexes and with heat shock protein 90 (HSP 90). Dulev S., Tchorbanov A., Uzounova M., Pashov A., and Vassilev T.
4. 15th European Immunology Congress, June 8-12, 2003, Rhodes, Greece.
4.1. Natural IgG antibodies in intravenous immunoglobulin (IVIg) preparations – insignificant artefacts or important immunomodulatory molecules? Tchorbanov A., Djoumerska I., Pashov A., and Vassilev T.
4.2. Reactivity of human natural IgG autoantibodies to serum proteins is directed mainly to circulating immunoglobulins. Djoumerska I., Tchorbanov A., Donkova-Petrini V., Pashov A., and Vassilev T.
4.3. Comparison of the molecular composition of diphtheria toxoid produced using meat-based broth and improved, low sensitizing semi-synthetic one. Dimitrov J., Tchorbanov A., Vassilev T.
5. 8th International Workshop on Autoantibodies and Autoimmunity, September 10-13, 2003, Berlin, Germany. Reestablishing tolerance to DNA in MRL/lpr mice. Vassilev T., Yomtova V., Chiang B.L., Tchorbanov A.
6. Aegean Conferences; Autoimmunity: Mecanisms and Novel Treatment Workshop, October 8-13, 2003, Mykonos, Greece.
6.1. Origin of natural IgG antibodies in therapeutic Immunoglobulin (IVIg) preparations. Djoumerska I., Tchorbanov A., Pashov A., and Vassilev T.
6.2. Effects of static and alternating magnetic fields on the binding of Natural Autoantibodies to self-antigens. Dimitrov J., Roumenin C., Djoumerska I., Tchorbanov A., and Vassilev T.
6.3. Reestablishing tolerance to DNA in MRL/lpr mice. Tchorbanov A., Yomtova V., Chiang B.L., Vassilev T.
2004
7. XIIth International Congress of Immunology, July 18-23, 2004, Моntreal, Canadа. Reestablishing tolerance to DNA in murine models of Lupus. Tchorbanov A., Yomtova V., Chiang B.L., Vassilev T. Clinical and Investigative Medicine Journal Supplement, Vol. 27, 2004.
8. 7th Dresden Symposium on Autoantibodies, September 1-4, 2004, Dresden, Germany. Selective Suppression of DNA Specific B Cells in lupus mice. Tchorbanov A., Voynova E., Mihaylova N., Chiang B.L., and Vassilev T.
9. 4th Balkan Congress of Immunology, September 5-8, 2004, Istanbul, Тurkey.
9.1. Breaking of Tolerance to DNA in Non-Autoimmune Mice By Immunozation with Natural DNA/Protein Complexes. Voynova E., Tchorbanov A., Todorov T., Pashov A., and Vassilev T. Turk J Immunol, 9-2 Supplement 2004.
9.2. Selective Suppression of DNA Specific B Cells in Murine Lupus. Tchorbanov A., Voynova E., Mihaylova N., Yomtova V., Chiang B.L., and Vassilev T. Turk J Immunol, 9-2 Supplement 2004.
9.3. The Autoreactivity of Therapeutic Immunoglobulin Preparation is Enhanced by some Fractionation Procedures. Djoumerska I., Tchorbanov A., Pashov A., and Vassilev T. Turk J Immunol, 9-2 Supplement 2004.
10. Days of Virology in Bulgaria, September 23-25, 2004, Sofia, Bulgaria. Pathological features of liver and spleen in rabbits with viral haemorrhagic disease. Alexandrov M., Peshev R., Lasarova S., Doumanova L., Bostandjieva R., and Tchorbanov A. Biotechnology and Biotechnological Equipment, 3/2004/18 Supplement.
2005
11. Keystone Symposia – Translational Medicine in Autoimmunity, January 8-13 2005, Big Sky, Montana, USA. Selective suppression of DNA-specific B cells in lupus mice. Vassilev T., Voynova E., Mihailova N., Chiang B.L., and Tchorbanov A.
12. 1st Meeting of Young Rheumatologist Across Europe, January 20 – 24, 2005, Reichenau an der Rax, Austria. Suppression of anti-DNA IgG antibody production and of disease activity in lupus mice by a hybrid antibody targeting an inhibitory B cell receptor. Mihailova N., Tchorbanov A., Voynova E., and Vassilev T.
13. Immunological Days in Pleven 2005, June 2-5, 2005, Pleven, Bulgaria.
13.1. Autoreactivity of Intravenous Immunoglobulin Preparations. Djoumerska I., Tchorbanov A., Pashov A., and Vassilev T.
13.2. Serum Polyclonal anti-alpha-elastin Antibodies in Patients with ankylosing spondylitis. Bogdanova M., Baydanov S., Tchorbanov A., Velkova A., and Stefanova K.
14. Vaccine congress, New Approaches to vaccine Development, 8 – 10 September, 2005, Berlin, Germany. Immunization with DNA chimeric molecule encoding a hemagglutinin peptide and scFv CD21 – specific antibody fragment induces long-lasting CTL response to influenza virus. Tchorbanov A., Prechl J., Maximova V., Voynova E., Ivanovska N., and Vassilev T.
15. Second Conference on Autoimmunity: Mechanisms and novel Treatments, 25-30 September 2005, Santorini, Greece.
15.1. Selective suppression by a chimeric antibody of DNA-cpecific B cells from Lupus patients. Voynova E., Tchorbanov A., Prechl J., Erdei A., and Vassilev T.
15.2. Selective suppression of histone-specific B cells of disease activity in lupus mice using a chimeric antibody. Mihaylova N., Tchorbanov A., Voynova E., and Vassilev T.
2006
16. 2nd Meeting of Young Rheumatologists Across Europe, January 12–15, 2006, Semmering, Austria.
16.1. Selective suppression of histone-specific B cells and affect on DNA-specific B cells in lupus mice leading to decrease of disease activity. Mihaylova N., Tchorbanov A., Voynova E., Vassilev T.
16.2. Suppression of an anti-DNA IgG antibody production by targeting an inhibitory B cell receptor in lupus patients. Voynova E., Tchorbanov A., Prechl J., Erdei A., Vassilev T.
17. 16th European Congress of Immunology, September 6-9, 2006, Paris, France.
17.1. Selective suppression by a chimeric antibody of DNA-cpecific B cells in a murine model of lupus. Voynova E., Tchorbanov A., Mihaylova N., and Vassilev T.
17.2. A chimeric molecule cross-linking BCR, inhibitory Fc-gamma RIIb and CD22 receptors suppresses autoreactive B cells. Mihaylova N., Tchorbanov A., Voynova E., and Vassilev T.
17.3. Specific suppression of DNA-binding B-cells from Lupus patients using a chimeric antibody. Nikolova K., Voynova E., Tchorbanov A., Prechl J., Erdei A., and Vassilev T.
17.4. DNA vaccine encoding a hemagglutinin peptide and scFv CD21 – specific antibody induces CTL response to influenza virus. Tchorbanov A., Prechl J., Maximova V., Voynova E., Ivanovska N., and Vassilev T.
17.5. Serum anti-alpha-elastin antibodies in patients with ankylosing spondylitis. Bogdanova M., Tchorbanov A., Velkova A., Stephanova K., Mihaylova N., Baydanoff S.
2007
18. 8th International Congress on SLE; Shanghai, China, May 23-27, 2007. Selective silencing of disease-associated B lymphocytes in lupus mice. Mihaylova N., Tchorbanov A., Voynova E., Vassilev T.
19. Third International conference: Bacterial, viral and parasitic infections in human and veterinary medicine, 15-16 June, 2007, Sofia, Bulgaria. Pathogenesis of the goose parvovirus infection. Alexandrov M., Lazarova S., Alexandrova R., Zacharieva S., Doumanova L., Tchorbanov A., Voynova E., Mihaylova N., Peshev R., Bumbarov V., Stoilov G.
20. 13th International congress of Immunology, August 21-25, 2007, Rio de Janeiro, Brazil. Selective silencing of autoreactive B lymphocytes by a chimeric antibody targeting two independent inhibitory surface receptors. Vassilev T., Mihaylova N., Voynova E., Tchorbanov A.
21. 5th Balkan congress for Microbiology, 24-27 October, 2007, Budva, Montenegro.
21.1. DNA vaccine encoding a haemagglutinin peptide and a scFv CD21-specific antibody induces CTL response. Tchorbanov A., Prechl J., Maximova V., Voynova E., Ivanovska N., Vassilev T. (Oral presentation)
21.2. Modulation of the Immune response using Rapana Thomasiana hemocyanin. Tchorbanov A., Mihaylova N., Idakieva K., Doumanova L.
2008
22. 3rd National congress of Immunology, 8-11 May, 2008, Varna, Bulgaria.
22.1. Generation of gene-engineered chimeric DNA molecules by recombinant technologies for specific therapy of autoimmune diseases. Tchorbanov A., Prechl J., Voynova E., Mihaylova N., Nikolova K.
22.2. Up-regulation by pooled immunoglobulin of the inhibitory Fc gamma IIb receptor on B lymphocytes from lupus-prone mice. Nikolova K., Mihaylova N., Voynova E., Djoumerska I., Tchorbanov A., Vassilev T.
23. Second congress of Virology, 28-31 May, 2008, Sofia, Bulgaria. New vaccine carriers: Immunogenicity of Rapana thomasiana hemocyanin conjugated subunit vaccines. Tchorbanov A., Idakieva K., Mihaylova N., Doumanova L. (Oral presentation)
24. 7th European Lupus Meeting, 7-10 May, 2008, Amsterdam, The Netherlands. Selective silencing of DNA-specific B lymphocytes by a chimeric antibody targeting their inhibitory Fc gamma IIb and CD22 receptors. Vassilev T., Voynova E., Tchorbanov A., Mihaylova N.
25. 6th International Congress on Autoimmunity, September 10-14, 2008, Porto, Portugal. Generation of gene-engineered chimeric DNA molecule by recombinent technologies for specific therapy of autoimmune diseases. Tchorbanov A., Voynova E., Mihaylova N., Nikolova K. (Oral presentation)
2009
26. CIS School in Systemic Autoimmune Diseases, April 1-5, 2009, Boston, MA, USA. Reestablishing tolerance to DNA in Humanized murine models of SLE. Tchorbanov, A. (Oral presentation)
27. BIT Life Sciences, 1st Annual International Congress of Antibodies, May 22-24, 2009, Beijing, China. Generation of Gene-engineered Chimeric DNA molecules by Recombinant technologies for specific therapy of Autoimmune diseases. Tchorbanov, A. (Oral presentation)
28. Second European Congress of Immunology, September 13-16, 2009, Berlin, Germany. European Journal of Immunology, Supplement 1/09.
28.1. Generation of gene-engineered chimeric DNA molecules by recombinant technologies for specific therapy of autoimmune diseases. Tchorbanov A., Mihaylova N., NikolovaK.
28.2. Selective silencing of disease-associated B-lymphocytes by chimeric molecules in SCID model of pristane-induced autoimmunity. Dimitrova I., Nikolova K., Mihaylova N., Tchorbanov A.
28.3. Reestablishing tolerance to DNA in humanized murine models of SLE. Kerekov N., Nikolova K., Mihaylova N., Tchorbanov A. (Oral presentation)
28.4. Rapana thomasiana hemocyanin as protein-carrier and bio-adjuvant of bacterial and viral proteins. Gesheva V., Nikolova K., Mihaylova N., Idakieva K., DoumanovaL., Tchorbanov A.
28.5. Intravenous immunoglobulin up-regulates the expression of the inhibitory FcγIIb B cell receptors. Nikolova K., Tchorbanov A., Djoumerska-Aleksieva I., Nikolova M., Vassilev T.
29. Neuropathology: the missing link between basic and clinical neurosciences, September 26th, 2009, Sofia, Bulgaria. Reestablishing tolerance to DNA in humanized murine models of SLE. Tchorbanov A. (Oral presentation)
30. 6th Balkan Congress of Microbiology, October 28-31, 2009, Ohrid, Macedonia. Rapana thomasiana hemocyanin as adjuvant of non-conjugated bacterial and viral proteins. Tchorbanov A., Gesheva V., Nikolova K., Mihaylova N., Idakieva K., Doumanova L.
2010
31. The Next Generation of Antibody Engineering Technologies and Antibody Therapeutics Development, January 25-27, 2010, Vienna, Austria. Generation of gene-engineered chimeric DNA molecules by recombinant technologies for specific therapy of autoimmune diseases. Tchorbanov A. (Oral presentation)
32. Balkan Joint meeting of Immunology and Clinical Allergology, 28 April 1 May, 2010, Sibiu, Romania.
32.1. Generation of gene-engineered chimeric DNA molecules by recombinant technologies for specific therapy of autoimmune diseases. Tchorbanov A., Gesheva V. and Kerekov N. (Oral presentation)
32.2. Reestablishing tolerance to DNA in humanized murine models of SLE. Kerekov N., Nikolova K., Mihaylova N., Tchorbanov A.
32.3. Elimination of disease-associated B-lymphocytes by chimeric molecules in SCID model of mouse lupus. Gesheva V., Kerekov N., Nikolova K., Mihaylova N., Tchorbanov A. (Oral presentation)
32.4. Treatment of allergen-specific B lymphocytes with chimeric protein-engineered molecules. Michova A., Nikolova M., Nikolov G., Muhtarova M., Gesheva V., Kerekov N., Tchorbanov A., Petrunov B.
33. 7th International Congress on Autoimmunity, May 5-9, 2010, Ljubljana, Slovenia. Reestablishing tolerance to DNA in humanized murine models of SLE. Tchorbanov A., Kerekov N., Nikolova K., Mihaylova N. (Oral presentation)
34. 29th Congress of the European Academy of Allergy and Clinical immunology, June 5-9, 2010, London, UK. Chimeric protein-engineered molecules as a putative model for allergen-specific B lymphocytes suppression. Nikolov G., Nikolova M., Michova A., Muhtarova M., Gesheva V., Kerekov N., Tchorbanov A., Petrunov B.
35. BIT’s 1st World Congress of Virus and Infections (WCVI 2010),July 31-August 3, 2010, BEXCO, Busan, South Korea. DNA and protein engineered vaccines containing a hemagglutinin peptide and a scFv CD21-specific antibody induce humoral and CTL response to Influenza virus. Kerekov N., Prechl J., Tchorbanov A. (Oral presentation)
36. 14th International Congress of Immunology, August 22 – 27, 2010, Kobe, Japan. Generation of gene-engineered chimeric DNA molecules by recombinant technologies for specific therapy of autoimmune diseases. Tchorbanov A., Gesheva V., Kerekov N.
37. 1st International Conference on Model hosts, September 5 – 10, 2010, Hersonissos, Crete, Greece. Humanized SCID mice models of SLE. Tchorbanov A., Kerekov N., PrechlJ., Mihaylova N. (Oral presentation)
38. 44th Days of preventive medicine, September 21 – 25, 2010, Nish, Serbia. DNA and protein engineered vaccines containing a hemagglutinin peptide and a scFv CD21-specific antibody induce humoral and CTL response to Influenza virus. Tchorbanov A. (Oral presentation)
39. Antigens and Lymphomas Meeting, October 7 – 8, 2010, Santorini, Greece. Activation-induced Cytidine deaminase as a druggable target for treatment of human B – cell Lymphomas. Dimitrova P., Tchorbanov A., Dimitrov Y., Vassilev T., Shivarov V.
40. Innovative strategies for vaccines: malaria, tuberculosis, HIV. November 4 – 6, 2010, Sorento, Italy.
40.1. Rapana thomasiana hemocyanin as adjuvant of non-conjugated bacterial and viral proteins. Gesheva V., Nikolova K., Mihaylova N., Idakieva K., Doumanova L., Tchorbanov A.
40.2. Immunization with a DNA chimeric molecule encoding a hemagglutinin peptide and a scFv CD21-specific antibody fragment induces strong long-lasting CTL response to influenza virus. Kerekov N., Prechl J., Mihaylova N., Ivanovska N., Tchorbanov A.
2011
41. 3rd International Conference on Drug Discovery and Therapy, February 7 – 10, 2011, Dubai, U.A.E. Experimental therapy in Humanized SCID mice models of SLE. Tchorbanov A. (Oral presentation)
42. ESF-JSPS Frontier Science Conference for Young Researchers: Cutting Edge Immunology and its Clinical Application, March 1-6, 2011, Hulshort, Netherlands. Target Silencing of Disease-Associated B-Lymphocytes by Chimeric Molecules in SCID Model of Pristane-Induced Autoimmunity. Mihaylova N., Tchorbanov A.
43. The first International Congress on Rheumatology and Autoimmunity CORA 2011, March 10 – 12, 2011, Florence, Italy. Elimination of autoreactive B cells in Humanized SCID mice models of SLE. Tchorbanov A. Kerekov N., PrechlJ., Mihaylova N. (Oral presentation)
44. FEMS 2011, 4th Congress of European Microbiologist, June 26 – 30, 2011, Geneva, Switzerland. DNA engineered vaccines containing a hemagglutinin peptide and a scFv CD21-specific antibody induce humoral and CTL response to Influenza virus. Tchorbanov A., Kerekov N., Prechl J.
45. Clinical Immunology Society’s (CIS) – School in Systemic Autoimmune Diseases, March 31 – April 3, 2011, Boston, MA, USA. Target Silencing of Disease-Associated B-Lymphocytes by Chimeric Molecules in SCID Model of Pristane-Induced Autoimmunity. Mihaylova N., Tchorbanov A.
46. Frontiers In Immunology Research – International Conference, July 1-4, 2011, Split, Croatia.
46.1. Generation of gene-engineered chimeric DNA molecules for specific therapy of autoimmune diseases. Gesheva V., Szekeres Z., Mihaylova N., Dimitrova I., Erdei A., Prechl J., Tchorbanov A. (Oral presentation)
46.2. Reestablishing tolerance to DNA in humanized murine model of SLE. Kerekov N., Nikolova K., Mihaylova N., Tchorbanov A.
47. BSI Summer school, July 5 – 8, 2011, St. Donat’s South Wales, UK. Generation of gene-engineered chimeric DNA molecules for specific therapy of autoimmune diseases. Gesheva V., Szekeres Z., Mihaylova N., Dimitrova I., Erdei A., Prechl J., Tchorbanov A.
48. 16th EFIS-EJI Simposium IMPULSE, September 3 – 6, 2011, Visegrad, Hungary.
48.1. Generation of gene-engineered chimeric DNA molecules for specific targeting of model viral antigens to activating receptors. Chausheva S., Gesheva V., Kerekov N., Tchorbanov A.
48.2. Generation of gene-engineered chimeric DNA molecules for specific therapy of autoimmune diseases. Gesheva V., Szekeres Z., Mihaylova N., Dimitrova I., Erdei A., Prechl J., Tchorbanov A.
49. South East European Immunology School (SEEIS), October 1- 4, 2011, Arandjelovac (Belgrade), Serbia.
49.1. Immunization with a DNA chimeric molecule encoding a hemagglutinin peptide and a scFv CD21-specific antibody fragment induces strong long-lasting CTL response to influenza virus. Kerekov N., Prechl J., Mihaylova N., Ivanovska N., Tchorbanov A.
49.2. Autoreactivity of human natural IgG autoantibodies is masked by serum and mucosal immunoglobulins. Manoylov I., Djoumerska-Alexieva I., Dimitrov J., Tchorbanov A.
49.3. Generation of gene-engineered chimeric DNA molecules for specific therapy of autoimmune diseases. Gesheva V., Szekeres Z., Mihaylova N., Dimitrova I., Erdei A., Prechl J., Tchorbanov A.
50. 7th Balkan Congress of Microbiology – Microbiologia Balkanica 2011, October 25 – 29, 2011, Belgrade, Serbia. Engineering of DNA Vaccine Containing a Hemagglutinin Peptide From Influenza Virus and a scFv CD21-Specific Antibody. Tchorbanov A., Kerekov N., Prechl J. (Oral presentation)
2012
51. Molecular Immunology & Immunogenetics Congress – MIMIC 2012, April 27 -29, 2012, Antalya, Turkey.
51.1. New approaches for selective immunotherapy of autoimmune diseases by engineered chimeric molecules. Mihaylova N., Tchorbanov A. (Oral presentation)
51.2. Serum and mucosal immunoglobulins block the autoreactive human IgG. Manoylov I., Djoumerska-Alexieva I., Dimitrov J., Tchorbanov A.
51.3. Novel DNA-binding cyanine dyes designed for flow cytometric analyses of apoptosis. Ivanova I., Tchorbanov A.
51.4. Immunization with a DNA chimeric molecule encoding a hemagglutinin peptide and a scFv CD21-specific antibody fragment induces strong long-lasting CTL response to influenza virus. Kerekov N., Prechl J., Mihaylova N., Ivanovska N., Tchorbanov A. (Oral presentation)
51.5. Functional elimination of double-stranded DNA-specific B Lymphocytes suppresses disease activity in SCID model of mouse lupus. Chausheva S., Mihaylova N., Gesheva V., Kerekov N., Nikolova K., Tchorbanov A.
52. 8th International Congress on Autoimmunity, May 9 – 13, 2012, Granada, Spain. Selective silencing of disease-associated B-lymphocytes by chimeric molecules in SCID model of pristane-induced autoimmunity. Tchorbanov A., Gesheva V, Nikolova K, Mihaylova N.
53. Workshop “Immune cell interactions: a mechanism for immune system control” – June 8, 2012, Sofia, Bulgaria.
53.1. Using of modified antibodies for specific Immunotherapy of autoimmune diseases. Mihaylova N., Tchorbanov A. (Oral Presentation)
53.2. Reestablishing tolerance to DNA in humanized murine models of SLE. Kerekov N., Mihaylova N., Prechl J., Todorov T., Erdei A.Tchorbanov A.
53.3. Novel DNA-biding cyanine dyes designed for flow cytometric analyses of apoptosis. Ivanova I., Kaloyanova S., Dimitrova P., Deligeorgiev T., Tchorbanov A.
53.4. Autoreactive IgG antibodies activity may be suppressed by other immunoglobulins in human serum and colostrums. Manoylov I., Djoumerska-Alexieva I., Dimitrov J., Tchorbanov A.
54. 3rd European Congress of Immunology ECI 2012, September 5 – 8, 2012, Glasgow, Scotland, UK.
54.1. Autoreactive IgG antibodies activity may be suppressed by other immunoglobulins in human serum and colostrums. Manoylov I., Djoumerska-Alexieva I., Dimitrov J., Tchorbanov A.
54.2. Genetically Engineered Chimeric Molecules Targeting Influenza A Viral Antigen. Mihaylova N., Kerekov N., Prechl J., Ivanovska N., Tchorbanov A.
54.3. Functional elimination of double-stranded DNA-specific B Lymphocytes suppresses disease activity in SCID model of mouse lupus. Chausheva S., Mihaylova N., Gesheva V., Kerekov N., Nikolova K., Tchorbanov A.
54.4. Bioadjuvant and Anti-cancer Properties of Hemocyanins in Experimental Models in vitro and in vivo. Gesheva V., Mihaylova N., Idakieva K., Tchorbanov A.
54.5. Flow cytometric analyses of apoptosis by new-synthesized DNA-biding cyanine dyes. Ivanova I., Kaloyanova S., Dimitrova P., Deligeorgiev T., Tchorbanov A.
54.6. Selective elimination of allergen-specific B lymphocytes with chimeric protein-engineered molecules. Kerekov N., Michova A., Nikolova M., Nikolov G., Muhtarova M., Petrunov B., Tchorbanov A.
54.7. Humanised SCID mice as an efficient models for selective treatment of autoimmune and allergic diseases. Kerekov N., Mihaylova N., Tchorbanov A. (Oral Presentation)
55. 4th EFIS – EJI (SEEIS2012), September 20 – 23, 2012, Sarajevo, Bosna and Herzegovina. Mouse models of Systemic Lupus Erythematosus. Tchorbanov A. (Oral presentation)
56. Symposiums “Akad. Chudomir Nachev”, October 13, 2012, Sofia, Bulgaria. New methods for targeted immunotherapy of autoimmune diseases with protein chimeric molecules. Mihaylova N., Tchorbanov A.
57. XXIV International Complement Workshop, October 10 – 15, 2012, Chania, Crete, Greece. Human CR1 as a target for selective treatment of autoimmune and allergic diseases in Humanised SCID mice. Kerekov N., Mihaylova N., Tchorbanov A. (Oral Presentation)
58. Scientific Conference “25 years flowcytometry in Bulgaria”, November 30, 2012, Pravetz, Bulgaria. FACS apoptosis analysis using new DNA-binding cianic dyes. Tchorbanov A. (Oral Presentation)
2013
59. 64th Annual Meeting of the German Society of Neurosurgery (DGNC), May 26-29, 2013, Düsseldorf, Germany. CXCR7 mediates angiogenesis in human glioma. Guentchev M., Tchorbanov A., Birner P., Tuettenberg J.
60. Immunology workshop “Modulation of Immune response by targeting of antigens to activating and inhibitory cell receptors by protein and gene-engineered chimeric molecules”, May 27 – 28, 2013, Nish, Serbia
60.1. Generation of protein and genetic engineered molecules for specific treatment of autoimmunity. Mouse models of Autoimmunity. Tchorbanov A. (Lecture)
60.2. Selective silencing of autoreactive or allergen-specific B and T cells in Humanized models of lupus and house dust allergy. Tchorbanov A. (Lecture)
60.3. New vaccines generation. Specific Immune response to model viral antigens – mouse and humanized model. Tchorbanov A. (Lecture)
60.4. Hemocyanins – natural adjuvants for viral and bacterial antigens. Tchorbanov A. (Lecture)
61. 15th International Congress of Immunology – ICI, August 22-27, 2013, Milan, Italy
61.1. The activity of autoreactive IgG antibodies may be blocked by human serum and breast milk immunoglobulins. Manoylov I., Djoumerska-Alexieva I., Dimitrov J., Tchorbanov A.
61.2. Selective elimination of allergen-specific B lymphocytes with chimeric protein-engineered molecules. Kerekov N., Michova A., Nikolova M., Nikolov G., Muhtarova M., Petrunov B., Tchorbanov A.
61.3. Genetically Engineered Chimeric Molecules Targeting Influenza A Viral Antigen. Ivanova I., Mihaylova N., Kerekov N., Erdei A., Prechl J., Tchorbanov A.
61.4. Helix pomatia Hc (HpH) hemocyanin as protein-carrier and bio-adjuvant of bacterial and viral proteins. Chausheva S., Gesheva V., Mihaylova N., Idakieva K., Doumanova L., Tchorbanov A.
61.5. Selective immunotherapy of lupus prone mice by biologically active peptides and simultaneous engagement of BCR and inhibitory B-cell receptors. Mihaylova N., Nikolova-Ganeva K., Nikolova M., Todorov T., Tchorbanov A.
61.6. Mouse SCID Models of Systemic Lupus Erythematosus. Kerekov N., Mihaylova N., Tchorbanov A.
62. IMPULSE, EFIS-EJI Symposium, August 31 – September 3, 2013, Matrahaza, Hungary
62.1. The activity of autoreactive IgG antibodies may be blocked by human serum and breast milk immunoglobulins. Manoylov I., Djoumerska-Alexieva I., Dimitrov J., Tchorbanov A.
62.2. Selective elimination of allergen-specific B lymphocytes with chimeric protein-engineered molecules. Kerekov N., Michova A., Nikolova M., Nikolov G., Muhtarova M., Petrunov B., Tchorbanov A.
63. 5th EFIS – EJI (SEEIS2013), September 20-23, 2013, Sofia, Bulgaria.
63.1. Mouse models of Systemic Lupus Erythematodes. Tchorbanov A. (Oral Presentation)
63.2. Genetically Engineered Chimeric Molecules Targeting Influenza A Viral Antigen. Hlebarska D., Kerekov N., Prechl J., Mihaylova N., Ivanovska N. and Tchorbanov A.
63.3. Induced restriction of the communication between autoimmune B and T lymphocytes in SCID model of mouse lupus. Balabanov I., Gesheva V., Kerekov N., Nikolova K., Mihaylova N., Tchorbanov A.
63.4. Viral Antigen Targeting by Genetically Engineered Chimeric Molecules. Kalacheva M., Kerekov N., Gesheva V., Mihaylova N., Prechl J., Tchorbanov A.
63.5. Helix pomatia Hc (HpH) hemocyanin as protein-carrier and bio-adjuvant of bacterial and viral proteins. Stefanova N., Chausheva S., Gesheva V., Mihaylova N., Idakieva K., Doumanova L., Tchorbanov A.
63.6. Functional elimination of autoreactive T cells by antibody therapy in murine model of Systemic lupus erythematosus. Chipinski P., Mihaylova N., Chausheva S., Todorova E., Kyurkchiev D., D’Acquisto F., Tchorbanov A.
63.7. Engineering of chimeric protein- antibodies for suppression of allergen-specific B lymphocytes. Bradyanova S., Kerekov N., Nikolov G., Mihaylova N., Nikolova M., Tchorbanov A.
63.8. New fluorogenic dyes for analysis of cellular processes by flow cytometry and confocal microscopy. Ilieva T., Nikolova K., Kaloyanova S., Mihaylova N., Stoitsova S., Chausheva S., Tchorbanov A.
64. 8th Balkan Congress of Microbiology, October 2-5, 2013, Veliko Tarnovo, Bulgaria.
64.1. Genetically engineered chimeric molecules targeting influenza viral antigen. Ivanova I., Mihaylova N., Kerekov N., Erdei A., Tchorbanov A.
65.2. Hemocyanines as adjuvants for non-conjugated bacterial and viral proteins. Gesheva V., Idakieva K., Chausheva S., Kerekov N., Nikolova K., Mihaylova N., Doumanova L., Tchorbanov A.
65. 8th Work Meeting “Biological activity of metals, syntetic compounds and natural products”, November 27-29, 2013, Sofia, Bulgaria.
65.1. Anti-cancer properties of gastropodan hemocyanins on murine model of colon adenocarcinoma. Gesheva, V., Chausheva, S., Mihaylova, N., Manoylov I., Doumanova, L., Idakieva, K., Tchorbanov, A.
65.2. Helix pomatia Hc (HpH) hemocyanin as protein-carrier and bio-adjuvant of bacterial and viral proteins. Stefanova N., Chausheva S., Gesheva V., Mihaylova N., Idakieva K., Doumanova L., Tchorbanov A.
2014
66. 5th Work Meeting „Experimental models and methods in biomedical research”, April 7–9, 2014, Sofia, Bulgaria.
66.1. Generation of gene-engineered chimeric DNA molecules for specific therapy of Autoimmune diseases. Gesheva V., Szekeres Z., Mihaylova N., Dimitrova I., Erdei A., Prechl J., Tchorbanov A.
66.2. Suppression of dsDNA-specific B Lymphocytes reduces disease symptoms in SCID model of mouse lupus. Balabanov I., Gesheva V., Kerekov N., Nikolova K., Mihaylova N., Todorov T., Nikolova M., Tchorbanov A.
66.3. Functional elimination of autoreactive T cells by antibody therapy in humanized SCID model of Systemic lupus erythematosus. Chipinski P., Mihaylova N., Bradyanova S., Chausheva S., Todorova E., Kyurkchiev D., D’Acquisto F., Tchorbanov A.
66.4. Functional elimination of autoreactive T cells by antibody therapy in MRL/lpr murine model of Systemic lupus erythematosus. Bradyanova S., Mihaylova N., Chausheva S., Todorova E., Kyurkchiev D., D’Acquisto F., Tchorbanov A.
66.5. Built-in adjuvanticity of Genetically and Protein Engineered Chimeric Molecules for targeting of Influenza A peptide epitopes. Hlebarska D., Kerekov N., Ivanova I., Mihaylova N., Nikolova M., Prechl J., Tchorbanov A.
67. Third International Symposium – WAD (World asthma Day), May 17, 2014, Prizren, Kosovo. Animal models of Allergy and Asthma. Tchorbanov A. (Oral Presentation)
68. 11th EFIS-EJI Tatra Immunology Conference 2014, September. 6-10, Štrbské Pleso, Slovakia.
68.1. Anti-cancer properties of gastropodan hemocyanins in murin model of colon adenocarcinoma. Gesheva V, Chausheva S, Mihaylova N, Manoylov I, Doumanova L, Idakieva K, Tchorbanov A.
68.2. Helix Pomatia hemocyanin-a novel bioadjuvant for viral and bacterial antigens. Chausheva S., Gesheva V, Stefanova N., Mihaylova N., Doumanova L., Idakieva K., Tchorbanov A.
69. 6th EFIS – EJI (SEEIS2014), September 26-29, 2014, Timisoara, Romania.
69.1. Anti-cancer properties of gastropodan hemocyanins on murine model of colon adenocarcinoma; Slavov S., Gesheva V., Idakieva K., Doumanova L., Tchorbanov A.
69.2. Selective elimination of allergen-specific B lymphocytes with chimeric protein-engineered molecules. Kolev K., Kerekov N., Michova A., Nikolov G., Nikolova M., Tchorbanov A.
69.3. Suppression of dsDNA-specific B Lymphocytes reduces disease symptoms in SCID model of mouse lupus. Delcheva N., Gesheva V., Kerekov N., Nikolova K., Mihaylova N., Nikolova M., Tchorbanov A.
70. 1st Black sea International Immunology school (BSIIS2014), 1 – 2 October 2014, Golden Sands – Varna, Bulgaria. Mouse models in Immunology. Tchorbanov A. (Lecture)
71. 4th National Congress of Immunology, 2-5 October, 2014, Golden Sands,Varna, Bulgaria.
73.1. Built-in adjuvanticity of Genetically and Protein Engineered Chimeric Molecules for targeting of Influenza A peptide epitopes. Hlebarska D., Kerekov N., Ivanova I., Mihaylova N., Nikolova M., Prechl J., Tchorbanov A.
73.2. New fluorogenic dyes for analysis of cellular processes by flow cytometry and confocal microscopy. Balabanov I., Nikolova K., Kaloyanova S., Mihaylova N., Stoitsova S., Chausheva S., Vasilev A., Lesev N., Dimitrova P., Deligeorgiev T., Tchorbanov A.
73.3. Modulation of the immune response by Gastropodan hemocyanins in metastasis model of glyoblastoma. Manoylov I., Gesheva V., Bradyanova S., Idakieva K., Doumanova L., Tchorbanov A.
73.4. Selective elimination of allergen-specific B lymphocytes with chimeric protein-engineered molecules. Kolev K., Kerekov N., Michova A., Nikolov G., Muhtarova M., Nikolova M., Petrunov B., Tchorbanov A.
73.5. Suppression of dsDNA-specific B Lymphocytes reduces disease symptoms in SCID model of mouse lupus. Delcheva N., Gesheva V., Kerekov N., Nikolova K., Mihaylova N., Nikolova M., Tchorbanov A.
73.6. Neutralization of autoreactive T cells by monoclonal antibody in pristane-induced mouse model of systemic lupus erythematosus. Chipinski P., Mihaylova N., Bradyanova S., Chausheva S., Todorova E., Kyurkchiev D., D’Acquisto F., Tchorbanov A.
73.7. Down-regulation of autoreactive T cells by antibody therapy in MRL/lpr murine model of Systemic lupus erythematosus. Bradyanova S., Mihaylova N., Chipinski P., Chausheva S., Todorova E., Kyurkchiev D., D’Acquisto F., Tchorbanov A.
73.8. Mouse models of Systemic Lupus Erythematodes. Tchorbanov A. (Oral Presentation)